KSC · 207940.KS
Samsung Biologics Co.,Ltd.
₩1,487,000+₩121,000 (+8.86%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.16% below the high.
Loading market information…
KOE · 048410.KQ · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Hyundai Bioscience Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 75.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Hyundai Bioscience Co., Ltd.’s forward annual dividend is ₩50 per share, paid annual. The forward yield is 0.93% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Hyundai Bioscience Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Hyundai Bioscience Co., Ltd. is a biotechnology firm dedicated to creating and commercializing bio-fusion technologies that enable the precise delivery of active compounds throughout the human anatomy. The company offers Vitabrid C12, a novel vitamin C product engineered to provide active vitamin C directly to the skin. Additionally, it is advancing organic-inorganic hybrid technology, which functions as a sophisticated drug delivery system. This system integrates bio-friendly minerals to ensure the targeted and efficient transport of active substances to specific sites, a capability also leveraged in its anticancer drug carrier innovations. The enterprise was established in 2000 and is headquartered in Seoul, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:38 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩1,487,000+₩121,000 (+8.86%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.16% below the high.
₩191,600+₩2,300 (+1.22%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.85% below the high.
₩211,500-₩8,500 (-3.86%)
Alteogen Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.68% below the high.
₩309,500+₩2,500 (+0.81%)
Samsung Epis Holdings’s quoted price sits in the lower half of its reported 52-week range, 59.96% below the high.
₩77,700-₩100 (-0.13%)
SK Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 46.08% below the high.
₩40,000+₩300 (+0.76%)
HLB Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.2% below the high.
₩61,500-₩2,500 (-3.91%)
LigaChem Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.67% below the high.
₩2,350-₩80 (-3.29%)
BNC Korea Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 61.97% below the high.
